MyBioSource

protein

Apolipoprotein A1 (ApoA1), Human Plasma

MBS173020

0.1 mg

140 USD

MBS173020

Protein

Apolipoprotein A1 (ApoA1), Human Plasma

Apolipoprotein A1

Lipoproteins A1; apo A1; Apolipoprotein A1 (APO A1), Human Serum - >=96% (SDS-PAGE)

apolipoprotein A-I preproprotein; Apolipoprotein A-I; apolipoprotein A-I; apo-AI; apolipoprotein A-I; Apolipoprotein A1Cleaved into the following 2 chains:Proapolipoprotein A-I; ProapoA-I; Truncated apolipoprotein A-IAlternative name(s):Apolipoprotein A-I(1-242)

APOA1; APOA1; Apo-AI; ApoA-I; ProapoA-I

APOA1_HUMAN

267

>= 96% (SDS-PAGE)

Liquid

At -20 degree C

Source: Human Serum. UNSPSC Code: 51131909

Recertification: 2 years. Protein: Typically >= 0.5 mg/mL (BCA or Lowry). Preservatives: Sodium Azide. pH: 7.4

Proteins; Antigens; Standards/controls; Native Proteins; Apolipoprotein A1 (apo A1)

Custom preparations, technical support, bulk quantities and aliquoting available. Single polypeptide chain in 245 amino acids with high alpha-helical content, major structurual component of high density lipoproteins, cofactor for lecthin:cholesterol acyltransferase, levels in general are inversely related to risk of coronary artery disease in humans. Human APO A1 is isolated by ultracentrifugation, delipidated and ion-exchange chromatography and is soluble in aqueous buffers at low concentrations (<50ug/mL) but due to amphipathic nature, APO A1 will self-associate into oligomers at high concentrations in the absence of chaotrupes (urea, guanidine hydrochloride). Apo-AI comprises ~70% of the protein moiety in HDL. It is a single polypeptide chain consisting of 245 amino acids with glutamic acid as the C-terminal residue and aspartic acid as the N-terminal residue. The molecular mass is reported to be 28.3 kDa. The protein is made up of one major isoform (pI 5.6) and two minor isoforms (pI 5.53 and 5.46). Apo-AI shows a high content of -helix structure. The amphipathic regions in the -helix structure seem to be responsible for lipid binding capacity. In aqueous solution, Apo-AI shows self-association with minor conformation change. Apo-AI activates lecithin-cholesterol (LCAT) acyltransferase, which is responsible for cholesterol esterification in plasma. Apo-AI levels in normal plasma are 90-130 mg/dL. Apo-AI levels may be inversely related to the risk of coronary disease.

4557321

NP_000030.1

NM_000039.1

28.3 kDa

ABC-family Proteins Mediated Transport Pathway 106573!!ABCA Transporters In Lipid Homeostasis Pathway 477112!!African Trypanosomiasis Pathway 194384!!African Trypanosomiasis Pathway 194323!!Amyloids Pathway 366238!!Binding And Uptake Of Ligands By Scavenger Receptors Pathway 771599!!Chylomicron-mediated Lipid Transport Pathway 106157!!Disease Pathway 530764!!Diseases Associated With Visual Transduction Pathway 771581!!FOXA2 And FOXA3 Transcription Factor Networks Pathway 137911

This gene encodes apolipoprotein A-I, which is the major protein component of high density lipoprotein (HDL) in plasma. The protein promotes cholesterol efflux from tissues to the liver for excretion, and it is a cofactor for lecithin cholesterolacyltransferase (LCAT) which is responsible for the formation of most plasma cholesteryl esters. This gene is closely linked with two other apolipoprotein genes on chromosome 11. Defects in this gene are associated with HDL deficiencies, including Tangier disease, and with systemic non-neuropathic amyloidosis. [provided by RefSeq, Jul 2008]

0.1 mg

140 USD